Norwegian biotech company Arctic Bioscience (Euronext Growth Oslo:ABS) has entered into an agreement for a new clinical study on psoriasis with its drug candidate HRO350, which is developed from herring roe oil, the company announced on Wednesday.
The three-year agreement with Smerud Medical Research International is worth NOK75m.
The phase IIb study aims to investigate the efficacy and safety of HRO350 and to establish the optimal dose.
More than 500 patients with mild to moderate psoriasis will be recruited in seven countries, including Norway, starting in the first quarter of 2022.
Arctic Bioscience recently raised NOK300m and was listed on the Euronext Growth market in Oslo on 24 February 2021.
(EUR1=NOK10.21)
Adagio Therapeutics begins global clinical trial of ADG20 for the treatment of COVID-19
UK expands COVID-19 vaccine combination trial to over-50s
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Frankel Named to Precision BioSciences B oard of Directors
Sobi launches phase 3 trial of efanesoctocog alfa in children with haemophilia A
Zealand Pharma and Boehringer Ingelheim to conduct Phase 2 trials of BI 456906 in obesity and NASH